Recruiting Ovarian Cancer Studies in Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of...
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in ...
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed,...
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid...
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy ...
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morni...
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
The main purpose of this study is to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of biomarker-guided novel anticancer agent(s) as monoth...
About Ovarian Cancer Clinical Trials in Oklahoma City
Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.
There are currently 7 ovarian cancer clinical trials recruiting participants in Oklahoma City, OK. These studies are seeking a combined 1,235 participants. Research is being sponsored by Regeneron Pharmaceuticals, Tubulis GmbH, University of Alabama at Birmingham and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ovarian Cancer Clinical Trials in Oklahoma City — FAQ
Are there ovarian cancer clinical trials in Oklahoma City?
Yes, there are 7 ovarian cancer clinical trials currently recruiting in Oklahoma City, OK. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Oklahoma City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Oklahoma City research site will contact you about next steps.
Are clinical trials in Oklahoma City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Oklahoma City studies also compensate for your time and travel.
What ovarian cancer treatments are being tested?
The 7 active trials in Oklahoma City are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.
Data updated March 2, 2026 from ClinicalTrials.gov